Aerogen and Philips have announced an agreement that “includes the acquisition of select assets solely related to Aerogen’s home-care business” by Philips. The announcement appears to refer to Aerogen’s Aeroneb Go vibrating mesh nebulizer. Philips made an undisclosed upfront payment and will make royalty payments “based on exploitation of the licensed technology.”
Aerogen CEO John Power commented, “This deal is an important step along Aerogen’s growth trajectory as it allows us to focus on expanding our core business in the acute care setting, whilst facilitating consistency of care for respiratory patients from hospital to home. Our acute care business has grown at a phenomenal rate over the past five years. Working with the global leaders in acute care ventilation and our independent distribution network we are today recognized as the gold standard for aerosol delivery in acute care ventilation. With several important new product releases planned for early 2014 we look forward to expanding our leadership position across all areas of aerosol drug delivery in the hospital environment.”
Philips Healthcare CEO of Home Healthcare Solutions Brent Shafer said, “This agreement is a key enabler in the development and marketing of respiratory drug delivery solutions to manage patients in the home. Inhalation therapy plays a key role in treating chronic respiratory problems and I believe that with Aerogen’s technology we are further expanding on our promise to improve people’s lives through meaningful innovation.’’
Both companies confirmed that “Aerogen’s acute-care and home ventilator drug delivery business is unaffected by the transaction and no employees will transfer to Philips as part of the agreement.”
Read the Aerogen press release.
Read the Philips press release.
